A Phase 3 Extension Study of RAD011 (Cannabidiol Oral Solution) in Patients With Prader-Willi Syndrome
- First Posted Date
- 2022-05-24
- Last Posted Date
- 2022-10-06
- Lead Sponsor
- Radius Pharmaceuticals, Inc.
- Registration Number
- NCT05387798
A Study to Assess RAD011 (Cannabidiol Oral Solution) for the Treatment of Participants With Prader-Willi Syndrome
- First Posted Date
- 2021-10-28
- Last Posted Date
- 2023-10-19
- Lead Sponsor
- Radius Pharmaceuticals, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT05098509
- Locations
- 🇺🇸
Maimonides Medical Center, Brooklyn, New York, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸MultiCare Institute for Research & Innovation, Tacoma, Washington, United States
A Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Participants With Prader-Willi Syndrome
- First Posted Date
- 2018-03-08
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Radius Pharmaceuticals, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT03458416
- Locations
- 🇺🇸
Institute for Research and Innovation | MultiCare Health System, Tacoma, Washington, United States
A Study to Assess Cannabidiol Oral Solution With Vigabatrin as Initial Therapy in Participants With Infantile Spasms
- Conditions
- Interventions
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2023-06-07
- Lead Sponsor
- Radius Pharmaceuticals, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT03421496
- Locations
- 🇺🇸
Nicklaus Children's Hospital, Miami, Florida, United States
🇺🇸Beaumont Children's Hospital, Royal Oak, Michigan, United States
🇺🇸Akron Children's Hospital, Akron, Ohio, United States
Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures
- First Posted Date
- 2017-11-28
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Radius Pharmaceuticals, Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT03355300
- Locations
- 🇺🇸
Akron Children's Hospital, Akron, Ohio, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Nicklaus Children's Hospital, Miami, Florida, United States
Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures
- First Posted Date
- 2017-11-08
- Last Posted Date
- 2023-07-21
- Lead Sponsor
- Radius Pharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT03336242
- Locations
- 🇺🇸
Nicklaus Children's Hospital, Miami, Florida, United States
🇺🇸Oregon Health and Science University, Portland, Oregon, United States
🇺🇸Pediatric Epilepsy and Neurology Specialists, Tampa, Florida, United States
Cannabidiol Oral Solution for the Treatment of Patients With Prader-Willi Syndrome
- First Posted Date
- 2016-07-26
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Radius Pharmaceuticals, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT02844933
- Locations
- 🇺🇸
The University of Kansas , Medical Center, Kansas City, Kansas, United States
🇺🇸University of Arizona, Tucson, Arizona, United States
🇺🇸University of Iowa, Iowa City, Iowa, United States
Study to Evaluate the Safety and Efficacy of RAD1901 in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms
- First Posted Date
- 2016-01-12
- Last Posted Date
- 2019-03-13
- Lead Sponsor
- Radius Pharmaceuticals, Inc.
- Target Recruit Count
- 139
- Registration Number
- NCT02653417
- Locations
- 🇺🇸
Women's Health Care Specialists P.C. - Beyer Research, Kalamazoo, Michigan, United States
A Study to Evaluate the Effects of RAD1901 in the Treatment of Vasomotor Symptoms in Postmenopausal Women
- First Posted Date
- 2009-04-03
- Last Posted Date
- 2018-09-26
- Lead Sponsor
- Radius Pharmaceuticals, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT00875420
- Locations
- 🇺🇸
Radius Health, Inc., Cambridge, Massachusetts, United States